These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11689138)

  • 1. Reservoirs for HIV infection and their persistence in the face of undetectable viral load.
    Sonza S; Crowe SM
    AIDS Patient Care STDS; 2001 Oct; 15(10):511-8. PubMed ID: 11689138
    [No Abstract]   [Full Text] [Related]  

  • 2. The challenge of viral reservoirs in HIV-1 infection.
    Blankson JN; Persaud D; Siliciano RF
    Annu Rev Med; 2002; 53():557-93. PubMed ID: 11818490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hidden HIV reservoirs: will eradication of the virus be possible?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Mar; ():18-9. PubMed ID: 11367451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation.
    Moreno S; Serrano-Villar S
    EBioMedicine; 2016 Nov; 13():31-32. PubMed ID: 27765640
    [No Abstract]   [Full Text] [Related]  

  • 7. 1st International Workshop on HIV Persistence during Therapy. St. Martin, December 10-12, 2003.
    Tossing G
    Eur J Med Res; 2004 Feb; 9(2):83-6. PubMed ID: 15090294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy.
    Honeycutt JB; Thayer WO; Baker CE; Ribeiro RM; Lada SM; Cao Y; Cleary RA; Hudgens MG; Richman DD; Garcia JV
    Nat Med; 2017 May; 23(5):638-643. PubMed ID: 28414330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.
    Rose R; Nolan DJ; Maidji E; Stoddart CA; Singer EJ; Lamers SL; McGrath MS
    AIDS Res Hum Retroviruses; 2018 Jan; 34(1):3-8. PubMed ID: 28691499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What do we need to do to cure HIV infection.
    Siliciano RF
    Top HIV Med; 2010; 18(3):104-8. PubMed ID: 20921575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV infected macrophages isolated from HIV+ patients with undetectable viral load undergoing combined antiretroviral treatment].
    Belmonte L; Baré P; Corti M; Bracco MM; Ruibal-Ares B
    Medicina (B Aires); 2001; 61(1):73-5. PubMed ID: 11265628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral load blips are of limited clinical significance.
    Lee PK; Kieffer TL; Siliciano RF; Nettles RE
    J Antimicrob Chemother; 2006 May; 57(5):803-5. PubMed ID: 16533823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 latency model for high-throughput screening.
    Micheva-Viteva S; Pacchia AL; Ron Y; Peltz SW; Dougherty JP
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5185-8. PubMed ID: 16304201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular basis of HIV-1 latency - Part II: HIV-1 reactivation and therapeutic implications].
    Cherrier T; Le Douce V; Redel L; Marban C; Aunis D; Rohr O; Schwartz C
    Med Sci (Paris); 2010 Mar; 26(3):291-5. PubMed ID: 20346279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
    Saksena NK; Potter SJ
    AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.
    Coiras M; López-Huertas MR; Pérez-Olmeda M; Alcamí J
    Nat Rev Microbiol; 2009 Nov; 7(11):798-812. PubMed ID: 19834480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART.
    Zalar A; Figueroa MI; Ruibal-Ares B; Baré P; Cahn P; de Bracco MM; Belmonte L
    Antiviral Res; 2010 Aug; 87(2):269-71. PubMed ID: 20471997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
    Pomerantz RJ
    Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
    Hezareh M
    Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.